Provider profile · Membership plus medication

Hims review: services, costs, and questions

Hims' current weight-loss membership and medication pathway, with attention to approved versus compounded product identity.

A teal laptop, a burgundy folder, a blank receipt, and an envelope on a desk.
Care and costs, illustrated. This is not a photograph of a listed provider or service.
Evidence boundary: This is a review of public information, not a hands-on treatment assessment. We have not independently audited pharmacies, clinician credentials, response times, or patient outcomes. We do not assign a star rating.

What the official information says

The official Hims weight-loss page advertises a care membership and treatment options. Current search and page research identify approved-product pathways as well as a changing history of compounded weight-loss offers.

The medication name and formulation on the actual prescription matter more than a generic GLP-1 heading. Ask whether you are being offered a branded product, a separately approved generic, or a compounded preparation; each has its own evidence and terms.

Pricing and the full bill

The current advertised membership is $39 for the first month and $149 per month afterward, billed separately from medication. Confirm the pharmacy price, dose, visit coverage, and any required ongoing membership. Different product pathways should not be combined into one low starting price.

A first-month price is not a reliable annual budget. Ask for the amount charged today, the renewal interval, the cost after any promotion, and whether medication, supplies, visits, labs, and shipping are included. Obtain cancellation and refund terms before paying, particularly if a prescription has not yet been approved.

Limitations that affect your decision

Earlier descriptions of the company's compounded offerings may be outdated. A current official quote should be the source of the treatment and billing details.

FDA's concerns about unapproved GLP-1 drugs apply to compounded formulations. Do not equate a compounded oral product with approved Wegovy tablets or infer an efficacy advantage from personalization language.

Medication trials evaluate specific formulations, doses, and study populations. A provider advertising semaglutide or tirzepatide has not thereby demonstrated that its own treatment produces the results of Wegovy or Zepbound trials. A compounded medicine is not FDA-approved and should not be described as an approved generic equivalent.

Questions to ask before enrollment

  • Which approved or compounded product is the current offer for, and what is the dispensing pharmacy?
  • Can I continue the prescription if I stop the membership?
  • What exact medicine, formulation, and device would I receive, and which pharmacy dispenses it?
  • Who prescribes in my state, and how do I obtain urgent clinical help?
  • What will I pay at maintenance, and when do renewals and cancellation deadlines occur?

Ask the prescribing clinician how your other medicines, diabetes treatment, pregnancy plans, gastrointestinal history, and follow-up needs affect eligibility. Check the dispensing pharmacy with the relevant state board. A reassuring website or testimonial does not replace those checks.

Use the current offer rather than the company's historical menu

The refreshed Hims page advertises branded medication pathways, including Wegovy tablets and other named products, with a required weight-loss membership. Earlier reports about compounded offers should not be assumed to describe the prescription available today. Ask the clinician and pharmacy for the actual product, formulation, indication, and presentation rather than relying on a generic GLP-1 heading.

The page notes that treatment is not available in all states and requires clinical eligibility. A displayed product is not a guarantee that a particular enrollee will receive it. If the offer is approved medication, its label supports the medicine's evidence; if a compound is proposed, it requires its own assessment and cannot inherit that approval. Hims' advertised treatment menu is also separate from independent verification of clinician credentials or the experience of obtaining follow-up.

Read the medication price and membership footnote together

Hims says the advertised medication prices exclude the required membership, which is $39 for the first month and automatically renews at $149 per month afterward. The membership does not guarantee a prescription. A medication headline starting at $149 therefore cannot be treated as a complete continuing monthly bill.

Ask for the pharmacy price at the prescribed maintenance dose and any change after a promotion. For illustration, a confirmed $299 medicine charge plus the advertised $149 recurring membership would total $448 before additional costs. That calculation applies only if your actual quote is $299; it is not a universal Hims price. Also ask whether medication can be obtained through the same pathway after canceling membership, and how the separate charges and refund terms operate if treatment is declined or interrupted.

Clarify what care-team access provides

The page advertises care-team access, nutrition and exercise guidance, and ongoing support. Ask which contact provides clinical decisions, how escalation and symptoms are reviewed, and whether additional visits or tests have fees. A general availability claim does not independently establish response time, emergency coverage, or clinician continuity.

If oral Wegovy is selected, review its fasting morning routine with the pharmacist and consider how it fits other medicines. If an injection is selected, obtain presentation-specific training. The medication trial referenced by a provider evaluates the studied medicine rather than proving Hims-specific outcomes. We have not measured adherence, pharmacy delivery, or medical response for enrolled patients. Evaluate the actual services and full bill alongside the appropriate product evidence, without treating a convenient platform as a clinical performance rating.

Sources and evidence

Provider sources support advertised services and terms. Clinical and regulatory sources explain medication and pharmacy considerations. These are distinct kinds of evidence.

  1. Hims weight-loss program
  2. FDA concerns with unapproved GLP-1 drugs used for weight loss
  3. FDA BeSafeRx: checking an online pharmacy
  4. Wegovy prescribing information, including tablets and Wegovy HD
  5. NIDDK: choosing a safe and successful weight-loss program
  6. FDA clarification of compounding policies as GLP-1 supply stabilizes